Pre-clinical data were presented at the TCT conference. OrbusNeich set to initiate patient enrolment in human clinical trial in fourth quarter.
Minimised ExtraCorporeal Circulation (MECC) system offers new approach to improve patient safety during heart surgery.
Data supporting the long-term safety and effectiveness of renal sympathetic denervation in treating patients with chronic hypertension were presented at the TCT conference.
Three-year Taxus ATLAS results show safety and efficacy advantages for Boston Scientific Taxus Liberte Stent.
Data on histopathology, mechanical integrity of the device, left ventricular reverse remodeling, and mitral valve annulus dimensions were released in San Francisco.
Mega has a smaller insertion point than traditional 50cc intra-aortic balloons and offers additional blood volume displacement for intra-aortic balloon counterpulsation.
Three-year results of the Medtronic's RESOLUTE trial include no new target lesion revascularisations and no instances of stent thrombosis.
New diagnostic tool combines St Jude Medical's PressureWire Aeris with GE's Mac-Lab Hemodynamic Recording System.
Latest findings from ENDEAVOR IV clinical trial also showed 91% reduction in risk of very late stent-related blood clots for Endeavor patients.
Boston Scientific announced on 21 September 2009 release of its CE-marked, next-generation iLab System Software for the iLab Ultrasound Imaging System.
PLATINUM clinical programme will support US and Japanese approval of new everolimus-eluting coronary stent system.
Valturna combines in a single pill valsartan, an angiotensin receptor blocker, with aliskiren, the only approved direct renin inhibitor.
Implantation of the GDS Accucinch System significantly reduced the patient's mitral regurgitation without requiring open heart surgery.
OrbusNeich's Genous Bio-engineered R stent is feasible and safe in patients who need coronary revascularisation before undeferrable non-cardiac surgery and have to discontinue dual antiplatelet therapy.
The addition of the angiotensin receptor blocker (ARB) Diovan to a non-ARB-based treatment regimen for high blood pressure provided a 45% relative risk reduction in cardiovascular events.
Company plans fourth-quarter launch for XIENCE V in China, the second-largest drug-eluting stent market in the Asia-Pacific region.
Acquisition expands vascular portfolio and provides Abbott with global leadership position in non-surgical treatment option for mitral valve repair.
According to the company, Avantgarde represents the latest and most advanced drug-free technology for the treatment of cardiovascular disease.
The procedures with the new lower-profile Ascendra 2 transapical delivery system were conducted at the University of Leipzig Heart Centre, Germany.
Kornelia Kotseva, Imperial College, London, UK, analyses the results of the EUROASPIRE surveys.
Results of the PLATO, RE-LY, PRAGUE-7, and PROTECT trials were presented during the conference in Barcelona, Spain.
Andre Rubboli, Bologna, Italy, analyses a polymer-free, Carbofilm coated stent eluting tacrolimus from abluminal reservoirs, which has been widely tested in patients with either stable or unstable coronary artery disease.
Study found that women may have a slightly higher risk following an acute coronary syndrome, but that these differences appear to be attributable to severity and type of syndrome.
TYPHOON and STRATEGY, two trials with long-term follow-up periods, showed sustained benefits for the Cypher stent when compared to bare metal stents.
The clinical program for Xience V studied patients in the US, Canada, Europe, South Africa and Asia-Pacific, and demonstrated excellent long-term results.
Patients with a certain genetic variation who received clopidogrel had a decreased platelet response to treatment according to a new study.
Study showed that, from 1995-2006, hospital 30-day death rates decreased significantly for Medicare patients hospitalised for a heart attack.
Chinese scientists presented one of the first studies suggesting that oxycholesterol may be the most serious cardiovascular health threat of all.
A website dedicated to the use of the Syntax Score, a novel angiographic tool used to measure the complexity of coronary artery disease, was launched at EuroPCR.
In the randomised NEVO RES-I trial, the Nevo sirolimus-eluting stent had significantly lower in-stent late lumen loss than the Taxus-Liberté device.
The systolic blood pressure goal of ?140mmHg was met by half of patients receiving the drug, according to a study presented at the American Society of Hypertension meeting.
Jamie S Sutherell, cardiology fellow at Cincinnati’s Children Hospital, US, analysis the lack of paediatric medical devices and off-label use.
Silvia G Priori spoke to Cardiovascular News about her career, research, joy in spending time with her two children, and the occasion she took beta-blockers before meeting Dr Mike Rosen.
At 38mm, it is the longest available drug-eluting stent and affords a more efficient treatment option for the estimated 8-10% of patients with long lesions.
Daiichi Sankyo and Lilly' Effient reduces thrombotic cardiovascular events in patients with acute coronary syndromes managed with percutaneous coronary intervention.
The number of PTCAs performed between January and March in Western Europe was 0.3% higher than in the Q4 2008 and 1.2% lower than in Q1 2008. The DES penetration rate was measured at 51.9%.
Study will assess Tryton side-branch stent in real-world settings. The device demonstrated excellent six-month clinical results in a first-in-man study of the system in 30 patients.
Approved to reduce the risk of cardiovascular hospitalization, Multaq will be launched this summer in the US by Sanofi-aventis.
The dataset demonstrated excellent results in high-risk patients with complex coronary lesions, including high procedural success rate and sustained safety.
Study shows that phone and Internet-based interventions make rehabilitation programmes more accessible after a heart attack.
Results from the largest and longest examination of enzyme replacement therapy in female demonstrated benefits on kidney function, heart function and burden of disease.
Investigation will study the performance of the Xience Prime everolimus-eluting stent, currently an investigational device, for the treatment of coronary artery disease.
Study presented at the XV International Symposium on Atherosclerosis shows novel synthetic statin is safe and well tolerated in combination with warfarin.
Trilipix delayed-release capsules in combination with rosuvastatin calcium achieved individual and combined lipid targets in patients with mixed dyslipidemia and type 2 diabetes.
The Society for Cardiovascular Angiography and Interventions encourages healthcare providers to apply the findings of BARI-2D, when appropriate, to their patients, as studied in this trial.
Analyses conducted from Pre-RELAX-AHF study showed that drug for acute heart failure treatment was the strongest independent predictor of improved longer-term outcomes.
Boston Scientific has received approval to market its new drug-eluting stent specifically designed for treating small coronary vessels.
Study analyses the outcomes of 47,967 patients entered into the Swedish Coronary Angiography and Angioplasty Registry between 2003 and 2006.
How much work cardiologists will take away from surgeons was one of the topics debated at the ESCVS meeting held in Warsaw, Poland, from 30 April–2 May.
BioInvent International AB has announced that its therapeutic antibody product candidate has reached the primary endpoint in its phase I trial, and was safe and well tolerated.
Research led by University of Calgary, Canada, shows ethnic variation in heart disease symptoms.
Analysis of data from 162 centres worldwide between 1995 and 2006 showed that tamponade caused the highest number of fatalities, followed by stroke and atrioesophageal fistula.
Substudy from the TRITON-TIMI 38 trial showed that patients who took prasugrel and had a reduced function of the CYP2C19 gene did not have an increased risk of cardiovascular events.
Dr Dirk J van Veldhuisen analyses the findings on the use of CRT for heart failure patients classes I and II and how the results will impact in future studies.
CID has announced that it has successfully defended European Patent 1277449 against an opposition filed by Conor Medsystem on proprietary drug-eluting stent technology.
Study showed that material commonly used in the production of such medical plastic devices as intravenous bags and catheters can impair heart function in rats.
Innovations in decision support, quality CPR and information management solutions help reduce critical time to lifesaving treatment.
Dr Maciej Banach, Medical University of Lodz, Poland, presented at The European Society of Cardiovascular Surgery meeting a range of studies showing the benefits of statin.
Results of a Chinese study showed that patients receiving drug-eluting stents had considerably higher three-year rates of target vessel revascularisation.
Study found that mice that lack the receptor for one type of the fatty compound prostaglandin have lower blood pressure and less atherosclerosis than their nonmutant brethren.
Software designed for the interpretation of coronary CT angiography helps radiologists determine which cases are high priority and should be read first.
OrbusNeich bio-engineered R stent showed low rate of stent thrombosis in studies presented at the Angioplasty Summit TCT Asia Pacific 2009.
Cardiovascular News talks to Professor Christian Hamm, Bad Nauheim, Germany, about his influences, current areas of research, and the challenges facing cardiology.
Eating fatty fish and marine omega-3 fatty acids, which are found in fish oil, seems to protect men, according to one of the largest studies to investigate the association.
The penetration rate was measured at 51.6% in Western Europe: this represents the fifth consecutive increase since the third quarter 2007.
Healthy individuals may be able to cut their risk of cardiovascular disease by 50 to 60% by taking a single pill that combines three blood pressure lowering drugs, a statin, and aspirin.
The benefits of rosuvastatin extend to preventing venous thromboembolism, according to analysis of the JUPITER study.
Professor Alfredo Galassi, Catania, Italy, analyses the techniques for the treatment of bifurcation lesions.
AnalyST Accel and Current Accel provide new alerts and insight into cardiac conditions such as atrial fibrillation and ischaemia.
Using clinical variables, American researchers created a method to estimate bleeding risk and help lessen the chances that heart attack patients will experience this complication.
Tea consumption simultaneously increased blood vessel reactivity and reduced both blood pressure and arterial stiffness.
The treatment of mitral regurgitation using the MitraClip system has demonstrated success in the first UK patients who have undergone the procedure.
Study shows screening did not result in a significant reduction in the rate of heart attacks or cardiac death compared to patients who were not screened.
The Design Zentrum Nordrhein-Westfalen has bestowed the red dot design award on the world's smallest cardiopulmonary support system Cardiohelp.
Aerobic exercise training appears safe for patients with heart failure and was associated with a modest reduction in the risk of death and hospitalisation.
Cognitive behavior therapy and supportive stress management appear more effective than usual care for treating depression after coronary artery bypass surgery.
Dr Erica Spatz tells how a new analysis estimated the number of older American adults who may benefit from statin therapy following the JUPITER trial results.
Dr Alfredo Galassi, Italy, launches practical handbook for interventional cardiologists willing to improve skills in the field of revascularisation of CTO.
Study showed that people in heart failure have less of the enzyme needed to activate a hormone that helps reduce extra sodium and fluid that tax the cardiovascular system.
The new system combines the Driver bare metal stent, platform of the company's coronary stents, with an improved delivery system.
A new report from the trial shows that the advantages of bypass surgery are less obvious once quality of life and economic data are included in the analysis.
The updated document includes an entirely new section on managing patients who are hospitalised with acute heart failure.
Study shows that the procedure not only failed to reduce deaths and hospitalisations in heart failure patients but also did not improve quality of life.
New analysis from the trial show that rosuvastatin significantly cut the risk of venous thromboembolism by 43% compared to placebo.
Comparative effectiveness study of 262,700 American patients was presented at the American College of Cardiology's 58th Annual Scientific Session in Orlando, USA.
Noninvasive sensor test is "highly predictive" of heart attack or stroke for people who are considered at low or moderate risk.
Standard and Poor’s has raised the company’s rating outlook to positive from negative, while affirming the company’s corporate credit rating at BB+.
New data from the American Centers for Disease Control and Prevention provide additional evidence that limiting amount of sodium can prevent and reduce hypertension.
Large cardiovascular outcomes study to be initiated will evaluate the effects of the drug once weekly compared to standard of care with traditional antidiabetes medications.
Study found that progression of a rare type of cardiomyopathy linked to a genetic mutation may be rapid and often results in early death.
This year's Artery Explorer tour kicks off this month, urging people across the USA to take action against atherosclerosis.
The hsCRP test used in the JUPITER trial will be available in the company's booth in the upcoming event in Orlando, USA.
Company will launch a complete image management system that provides image management software and image acquisition, storage, display and web distribution devices.
Dr Ascan Warnholtz, University of Mainz, Germany, puts into perspective the results of the trial and the use of myocardial fractional flow reserve.
Results of a study performed to assess the clinical and angiographic long-term outcome after implanting drug-eluting stents were published in JACC Cardiovascular Interventions.
Abbott has announced the initiation of the next phase of the ABSORB trial to evaluate the safety and performance of the fully bioabsorbable drug eluting coronary stent.
Document helps physicians deciding whether it is appropriate to treat chest pain with medical therapy alone or prescribe medical therapy and also perform revascularisation.
The aim of the campaign is to improve quality of care and reduce mortality rates among acute coronary patients.
According to study published in the Journal of the American College of Cardiology, both stents provide comparable clinical and angiographic outcomes.
The SOS study showed that Taxus reduced restenosis, target lesion revascularisation, and target vessel failure compared with bare metal stents.
St Jude Medical has announced European CE mark approval of its Genesis neurostimulation system for managing chronic angina.
Catania coronary stent with NanoThin Polyzene-F shows sustained 12-month benefit in the treatment of de novo lesions.
Cordis has announced plans to launch NEVO II, a global, head-to-head clinical trial to compare the Nevo sirolimus-eluting coronary stent to the Abbott's Xience V everolimus-eluting stent.
0
Survey shows that large proportions of European coronary patients are failing to achieve lifestyle, risk factor and therapeutic targets for the prevention of further disease.
Data in The Lancet demonstrate Abbott's device is absorbed within two years, leaving behind blood arteries that appear to move and function similar to untreated vessels.
BridgePoint Medical has completed the first human clinical case using its CrossBoss CTO Catheter and Stingray CTO Re-Entry System.
Report proposes an explanation for the apparent paradox of improved prevention, falling mortality rates but stable rates of hospitalisation.
Results of the trial were published in the Journal of the American College of Cardiology showed device is easy to use and provides excellent hemodynamic support.
The Voyager NC is a balloon dilatation catheter designed to optimise the treatment of patients with coronary artery disease during angioplasty procedures.
Following an acute coronary syndrome, patients who receive a medication to reduce the risk of gastrointestinal bleeding that may be associated with the use of clopidogrel and aspirin have an increased risk of hospitalisation or death.
Patients with abnormal diastolic function in the left ventricle have a substantially lower maximum capacity for exercise, according to a study published in the JAMA.
An examination of clinical practice guidelines for treating cardiovascular disease finds that current recommendations are largely based on lower levels of evidence or expert opinion.
In the not-too-distant future, a simple blood test may predict the genetic risk of suffering a heart attack, according to research from the McMaster University, Canada.
New developments for prevention/reduction of atherothrombotic events in patients with acute coronary syndromes who undergo PCI were presented at the VEITHsymposium 2008.
Study shows that some patients who received beta-blockers before and around the time of non-cardiac surgery appear to have higher rates of infarction and death within 30 days of the procedure.
Many among the abstracts at the AHA Scientific Sessions 2008 were focused on the setting of ACS. Two such sessions were included among the high-profile Late-Breaking Clinical Trials. A third examined treatment for children with familial hypercholesterolemia.
Cardiovascular News talks to Dr Kim Fox, immediate past-president of the European Society of Cardiology (ESC), about getting into cardiology, his interest in ischaemic heart disease and the future of cardiovascular medicine.
0
0
0
0
0
The European Society for Cardiology Committee for Practice Guidelines has released three new sets of updated guidelines in these three areas of cardiovascular care.
Two studies showed that statin treatment with Crestor had no effect in patients with chronic heart failure, while a one-a-day capsule of omega-3 can reduce mortality and admission to hospital for cardiovascular reasons.
Results from a post-hoc analysis of the data from the trial show that dronedarone reduces stroke risk.
The TIME-CHF trial showed that the use of natriuretic-peptide levels rather than symptoms alone to guide the medical management of heart failure failed to influence the primary endpoint of hospitalisation-free survival over 18 months.
Study was designed to investigate how the standards set in 2003's Third Joint European Task Force guidelines on cardiovascular disease prevention have been put into practice.
Results from a new study suggest that patients' brains may retain the capacity to rewire through a treadmill exercise programme months or years after conventional physical therapy has ended.
Results from a Canadian study show that only 40% of ischaemic stroke patients who had atrial fibrillation had received warfarin before their stroke.
A project involving institutions from six European countries, euHeart has been created to improve the diagnosis, therapy and treatment of cardiovascular disease.
A new review of clinical trials, published online in Nature in August, revealed that the number of registered cardiology studies declined during a recent two-year period.
Study over the first five years of life found that there is a link between the pace of weight gain in early childhood and high blood pressure in adulthood.
Among key sessions at 2008 American Society of Hypertension (ASH) Annual Meeting were several reports on combination therapies, including those differentiating effects among specific subgroups.
Innovative prototype of a novel heart valve resection tool is based on foldable nickel-titanium (NiTi) blades.
Data show that Angiomax (bivalirudin) provides acute coronary syndrome patients who are undergoing PCI with similar results from ischaemic events and death versus standard therapy.
The FAME trial showed that routine measurements of fractional flow reserve during percutaneous coronary intervention compared to angiographic approach reduces rate of composite endpoint of death.
In JUPITER (Justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin), a clinical trial enrolling individuals who do not currently qualify for statin therapy, rosuvastatin significantly reduced all-cause mortality by 20%.
The aim of this article is to review the incidence and all the possible causes and consequences of a suboptimal stent expansion.
Professor Alain Cribier i...
Professor Fausto Pinto discusses his major influences, his career achievements and his passion for travelling, books and music.
The Editor of Vascular News, Professor Roger Greenhalgh, Imperial College, London, writes a personal appreciation of DeBakey.
0
A market report from BIBA Research shows that drug-eluting stents (DES) penetration rate in Western and Central Europe increased by 1.1% to 47.6% in the second quarter 2008.
